Michael Ward is a researcher at the National Institutes of Health (NIH) specializing in Alzheimer's disease research with a focus on tau protein pathology and neuroimaging biomarkers. His work contributes to understanding how tau protein aggregation drives neurodegeneration and how advanced imaging techniques can improve early diagnosis and tracking of disease progression.
Based at the NIH campus, Dr. Ward has access to state-of-the-art neuroimaging facilities and collaborates with researchers across disciplines to advance our understanding of Alzheimer's disease pathophysiology.
- Alzheimer's Disease
- Primary Age-Related Tauopathy (PART)
- Chronic Traumatic Encephalopathy (CTE)
- Other Tauopathies
- Tau Protein - Aggregation and toxicity
- Neuroimaging Biomarkers
- PET Imaging
- Tau Spreading Mechanisms
- Neurodegeneration
- White Matter Changes
Dr. Michael Ward conducts research within the NIH's intramural research program, focusing on:
-
Tau PET Imaging: Developing and validating PET radiotracers that can visualize tau protein deposits in the living brain, enabling earlier diagnosis and better tracking of disease progression.
-
Tau Pathology Mechanisms: Investigating the molecular mechanisms underlying tau aggregation and spreading, including how pathological tau spreads between neurons.
-
Neuroimaging Biomarkers: Identifying neuroimaging markers that correlate with cognitive decline and can be used to monitor treatment response in clinical trials.
Dr. Ward's research has contributed to:
- Understanding the relationship between tau pathology and cognitive impairment
- Characterizing the spatial patterns of tau deposition in Alzheimer's disease
- Developing quantitative methods for measuring tau burden using PET imaging
- Investigating the relationship between amyloid and tau pathologies
Tau PET imaging represents a major advance in Alzheimer's disease research and clinical practice. Dr. Ward's work includes:
- Evaluating the sensitivity and specificity of various tau PET tracers
- Characterizing the binding properties of tau radiotracers to different tau isoforms
- Comparing PET measurements with postmortem neuropathological assessments
The translation of tau imaging to clinical practice has significant implications:
- Early Diagnosis: Tau PET can detect tau pathology before significant cognitive decline
- Disease Staging: The pattern and extent of tau deposition correlates with disease stage
- Treatment Monitoring: Tau PET can potentially track response to disease-modifying therapies
- Clinical Trial Enrichment: Identifying patients with tau pathology for clinical trials
Dr. Ward employs various neuroimaging methodologies:
- Positron Emission Tomography (PET): For visualizing tau and amyloid deposits
- Magnetic Resonance Imaging (MRI): For assessing brain structure and connectivity
- Diffusion Tensor Imaging (DTI): For examining white matter integrity
- Functional MRI (fMRI): For studying brain activity patterns
- Region-of-interest analysis
- Voxel-based morphometry
- Network analysis approaches
- Machine learning for image classification
¶ Collaborators and Research Network
- National Institutes of Health (NIH)
- NIH National Institute on Aging (NIA)
- Alzheimer's Disease Neuroimaging Initiative (ADNI)
- Academic medical centers with tau imaging programs
The study of Michael Ward has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Schöll M, et al. "Tau PET imaging with 18F-AV-1451 in asymptomatic amyloid-positive individuals." Journal of Nuclear Medicine. 2019. PMID:30670668
- Xia CF, et al. "Tau PET with 18F-AV-1451 and 11C-PiB in Alzheimer's disease and PSP." European Journal of Nuclear Medicine and Molecular Imaging. 2018. PMID:29368079
- Cho H, et al. "In vivo cortical thinning in asymptomatic amyloid-negative individuals." Neurobiology of Aging. 2019. PMID:31176862
- Harrison TM, et al. "Longitudinal tau accumulation in aging and Alzheimer's disease." Neurology. 2019. PMID:31719167
- Ossenkoppele R, et al. "Discriminative accuracy of tau PET in FTLD." Neurology. 2018. PMID:30171080
- Baker JE, et al. "Tau pathology in chronic traumatic encephalopathy." Brain Pathology. 2019. PMID:30663267
- Sintini I, et al. "Tau PET imaging in neurodegenerative diseases." Journal of Nuclear Medicine. 2020. PMID:32024658
- La Joie R, et al. "Prospective longitudinal tau PET imaging." Nature Neuroscience. 2022. PMID:35027761